The PennZone

  • Home
  • Business
  • Health
  • Technology
  • Non-profit
  • Financial
  • Construction
  • Sports
  • Services

Utah attempts to legalize placenta cell therapy
The PennZone/10266985

Trending...
  • T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
  • Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation
  • $80M+ Backlog as Florida Statewide Contract, Federal Wins, and Strategic Alliance Fuel Next Phase of AI-Driven Cybersecurity Growth: Cycurion $CYCU
Parent's Guide to Cord Blood Foundation
Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

BROOKEVILLE, Md. - PennZone -- Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

Parent's Guide to Cord Blood Foundation is a small non-profit in the biotech space. We are the first to break the story that the Utah state legislature did not realize what they were voting for when they passed Utah S.B. 199.

More on The PennZone
  • Philadelphia Startup NoPlex Creates an ADHD/Neurodiversity-Focused Alternative to Productivity Apps
  • Tiger-Rock Martial Arts Appoints Jami Bond as Vice President of Growth
  • Super League (N A S D A Q: SLE) Enters Breakout Phase: New Partnerships, Zero Debt & $20 Million Growth Capital Position Company for 2026 Acceleration
  • Finland's Gambling Reform Promises "Single-Click" Block for All Licensed Sites
  • Private Keys Are a Single Point of Failure: Security Advisor Gideon Cohen Warns MPC Technology Is Now the Only Defense for Institutional Custody

The FDA still considers unapproved stem cell therapies to be illegal, and when it comes to drug regulations, federal law takes supremacy. This is not the same as states ignoring federal law and legalizing recreational drugs. In the case of stem cell therapy, patients that receive unregulated products with insufficient oversight could suffer serious adverse events. The new law Utah S.B. 199 is going to trigger a showdown between the federal government and Utah. Doctors who administer therapy to patients under the new Utah law could be sued by the Dept. of Justice. At a bare minimum, we are calling for the state of Utah to establish oversight of this arena before patients are hurt.

Contact
Frances Verter, PhD
***@parentsguidecordblood.org


Source: Parent's Guide to Cord Blood Foundation

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Dominic Pace Returns to the NCIS Franchise With Guest Role on NCIS: Origins
  • Anderson Periodontal Wellness Attends 5th Joint Congress for Ceramic Implantology
  • UK Financial Ltd Completes Full Ecosystem Conversion With Three New ERC-3643 SEC-Ready Tokens As MCAT Deadline Closes Tonight
  • AI Real Estate Company Quietly Building a National Powerhouse: reAlpha Tech Corp. (N A S D A Q: AIRE)
  • Inkdnylon Expands National Uniform Embroidery Services
  • Appliance EMT Expands Appliance Repair Services to Portland, OR and Vancouver, WA
  • Next Week: The World's Best Young Pianists Arrive in Music City for the 2025 Nashville International Chopin Piano Competition
  • Revenue Optics Builds Out Its Dedicated Sales Recruiting Firm with Strategic Addition of Christine Schafer
  • Hydrofast Elevates the Holiday Season: The C100 Countertop RO System Merges Smart Tech with Wellness for the Perfect Christmas Gift
  • Melospeech Inc. Accepts Nomination for HealthTech Startup of the Year
  • Flower City Tattoo Convention Draws Record Attendance in Rochester, NY
  • KIKO NATION TOKEN (Official Release)
  • Verb™ Presents Features Vanguard Personalized Indexing: Utilizing Advanced Tax-Loss Harvesting Technology
  • Psoriasis Drugs Market Poised to Hit 20 Billion Dollars in 2025 says SNS Research in Latest Report
  • UK Financial Ltd Announces A Special Board Meeting Today At 4PM: Orders MCAT Lock on CATEX, Adopts ERC-3643 Standard, & Cancels $0.20 MCOIN for $1
  • 6 Holiday Looks That Scream "Old Money" But Cost Less Than Your Christmas Tree
  • Tickeron Launches Next-Gen AI Corridor Bots: Consistent Exits for Stocks and ETFs
  • From Cheer to Courtroom: The Hidden Legal Risks in Your Holiday Eggnog
  • Controversial Vegan Turns Rapper Launches First Song, "Psychopathic Tendencies."
  • Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation

Popular on PennZone

  • Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders - 538
  • BumblebeeSmart Introduces Rounded Busy Board Set for Preschoolers - 217
  • Light Her Way Launches New Cohort of Board of AdviseHERS to Prepare Women for Board-Ready Leadership - 104
  • 5,000 Australians Call for Clarity: NaturismRE's Petition Reaches Major Milestone
  • Corcoran DeRonja Real Estate Welcomes Siobhán Simões to Its Growing Team
  • Heritage At Manalapan - A New Luxury Single Family Home Community Coming Late 2025
  • BITE Data raises $3m to build AI tools for global trade compliance teams
  • purelyIV Expands Wellness Services with Flu/COVID Testing and Menopause Coaching & Treatment
  • Turbo vs. Experts: Tracking OddsTrader's AI Performance at the NFL's Midpoint
  • CCHR Supports Call to End Coercive Psychiatry at World Mental Health Congress

Similar on PennZone

  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
  • FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
  • Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
  • $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
  • U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf
  • Global Innovators Take the Stage at the WorldUpstart Accelerator Showcase in Philadelphia
  • Phinge's Netverse to Redefine Clinical Trial Safety and Data Integrity with Netverse Patented, Hardware-Verified Platform
  • MDRN MUSE Expands Insurance Network Coverage to Include Delta Dental & Cigna
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us